Clinical Trials · NCT06972992
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Ascletis Pharma (China) Co., Limited
- Enrollment
- 28
- Start date
- Apr 2025
- Locations
- 1 site, United States
- Primary endpoint
- Adverse events